BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26449730)

  • 1. Acral verruca-like presentation of chronic graft-vs.-host disease.
    Park JH; Lester L; Kim J; Kwong BY
    J Cutan Pathol; 2016 Mar; 43(3):236-41. PubMed ID: 26449730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased bacterial infections after transfusion of leukoreduced non-irradiated blood products in recipients of allogeneic stem cell transplants after reduced-intensity conditioning.
    Jaime-Pérez JC; Villarreal-Villarreal CD; Salazar-Riojas R; Méndez-Ramírez N; Vázquez-Garza E; Gómez-Almaguer D
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):526-30. PubMed ID: 25498924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.
    Hamilton BK
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):228-235. PubMed ID: 30504315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isomorphic cutaneous graft-versus-host disease reaction after ultraviolet exposure: clinical, histological and direct immunofluorescence studies of four allo-transplanted patients.
    Vassallo C; Brazzelli V; Zecca M; Locatelli F; Alessandrino PE; Borroni G
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):913-8. PubMed ID: 19586515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
    Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
    Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of chronic oral graft-vs-host disease following pediatric hematopoietic stem cell transplantation.
    da Fonseca MA; Hong C
    Pediatr Dent; 2008; 30(2):98-104. PubMed ID: 18481573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
    Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
    Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
    Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
    El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
    Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe acute gastrointestinal graft-vs-host disease: an emerging surgical dilemma in contemporary cancer care.
    Irani JL; Cutler CS; Whang EE; Clancy TE; Russell S; Swanson RS; Ashley SW; Zinner MJ; Raut CP
    Arch Surg; 2008 Nov; 143(11):1041-5; discussion 1046. PubMed ID: 19015460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical manifestations of graft-versus-host disease.
    Cornejo CM; Kim EJ; Rosenbach M; Micheletti RG
    J Am Acad Dermatol; 2015 Apr; 72(4):690-5. PubMed ID: 25641626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation.
    Lorenz F; Marklund S; Werner M; Palmqvist R; Wahlin BE; Wahlin A
    Sci Rep; 2015 Jan; 5():7920. PubMed ID: 25605402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.
    Klyuchnikov E; El-Cheikh J; Sputtek A; Lioznov M; Calmels B; Furst S; Chabannon C; Crocchiolo R; Lemarié C; Faucher C; Bacher U; Alchalby H; Stübig T; Wolschke C; Ayuk F; Reckhaus ML; Blaise D; Kröger N
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):382-6. PubMed ID: 24321747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
    Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
    Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bowel ultrasonography as an aid for diagnosis of intestinal acute graft-versus-host-disease after allogeneic haematopoietic stem cell transplantation.
    Calabrese E; Zorzi F; Visconti E; De Angelis G; Cerretti R; Del Vecchio Blanco G; Picardi A; Cudillo L; Postorino M; Franceschini L; Biancone L; Arcese W; Pallone F
    Dig Liver Dis; 2013 Nov; 45(11):899-904. PubMed ID: 23680035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.